Danaher

US · DHR #143 by market cap Listed 1970

212.08 -6.41 -2.93%

Live - 5344 symbols - heartbeat 334s ago · 2026-10-08 10:10

Pre-market 217.40 -0.50%

After-hours 218.49 0.00%

Overnight 218.50 +0.00%

Market cap: 149.09B
P/E (TTM): 37.67
P/B: 2.84
EPS: 5.05
Div yield: 0.68%
52W pos: 64%

Reader sentiment Are you bullish or bearish on DHR?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 4.24, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +2.90% YoY

Margins

Gross margin: 59.11%
Operating margin: 19.09%
Net margin: 14.71%

Key ratios & quality

Enterprise value: 163.09B
Altman Z-Score: 4.24

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	17.05B	17.91B	22.28B	24.80B	26.64B	23.89B	23.88B	24.57B
Gross profit	9.51B	9.98B	12.48B	15.24B	16.19B	14.03B	14.21B	14.52B
Selling & admin expenses	5.39B	5.59B	6.90B	6.81B	7.12B	7.33B	7.76B	8.24B
Research & development	1.06B	1.13B	1.35B	1.50B	1.53B	1.50B	1.58B	1.60B
Operating profit	3.06B	3.27B	4.23B	6.39B	7.54B	5.20B	4.86B	4.69B
Pretax profit	2.96B	3.31B	4.50B	6.51B	7.15B	5.04B	4.65B	4.23B
Tax	556.00M	873.00M	849.00M	1.06B	818.00M	823.00M	747.00M	633.00M
Net profit	2.65B	3.01B	3.65B	6.43B	7.21B	4.76B	3.90B	3.61B
Basic EPS	4	4	5	9	10	6	5	5
Diluted EPS	3.74	4.05	4.89	8.61	9.66	6.38	5.29	5.05

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	5.74B	5.94B	6.05B	6.84B	5.95B	6.27B
Gross profit	3.51B	3.52B	3.52B	3.97B	3.59B	3.61B
Selling & admin expenses	1.86B	2.36B	1.99B	2.03B	1.86B	2.07B
Research & development	379.00M	403.00M	378.00M	438.00M	387.00M	412.00M
Operating profit	1.27B	760.00M	1.15B	1.50B	1.34B	1.13B
Pretax profit	1.13B	655.00M	1.08B	1.37B	1.24B	1.08B
Tax	175.00M	100.00M	168.00M	190.00M	206.00M	208.00M
Net profit	954.00M	555.00M	908.00M	1.20B	1.03B	870.00M
Basic EPS	1	1	1	2	1	1
Diluted EPS	1.32	0.77	1.27	1.68	1.45	1.23

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	7.09B	25.60B	13.80B	11.65B	15.88B	13.94B	9.50B	12.76B
Cash & ST investments	787.80M	19.91B	6.04B	2.59B	6.00B	5.86B	2.08B	4.62B
Inventory	1.63B	1.63B	2.29B	2.77B	2.77B	2.59B	2.33B	2.49B
Total assets	47.83B	62.08B	76.16B	83.18B	84.35B	84.49B	77.54B	83.46B
Total current liabilities	4.84B	4.93B	7.40B	8.14B	8.39B	8.27B	6.80B	6.81B
Short-term debt	51.80M	370.00M	200.00M	215.00M	758.00M	1.88B	678.00M	201.00M
Long-term debt	9.69B	21.52B	21.19B	22.17B	19.09B	16.71B	15.50B	18.42B
Total liabilities	19,605,800,000.00	31,800,000,000.00	36,384,000,000.00	38,007,000,000.00	34,260,000,000.00	30,998,000,000.00	27,992,000,000.00	30,923,000,000.00
Total equity	28.23B	30.28B	39.78B	45.18B	50.09B	53.49B	49.55B	52.54B
Retained earnings	25.16B	24.17B	27.16B	32.83B	39.21B	41.07B	44.19B	46.89B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	9.53B	11.00B	9.61B	12.76B	13.94B	13.38B
Cash & ST investments	1.99B	2.96B	1.53B	4.62B	5.70B	4.35B
Inventory	2.53B	2.69B	2.67B	2.49B	2.61B	3.26B
Total assets	79.12B	81.62B	79.90B	83.46B	83.54B	92.37B
Total current liabilities	6.65B	6.79B	6.32B	6.81B	7.46B	8.11B
Short-term debt	501.00M	502.00M	23.00M	201.00M	923.00M	1.41B
Long-term debt	15.98B	16.85B	16.83B	18.42B	17.56B	25.15B
Total liabilities	28,259,000,000.00	29,278,000,000.00	28,817,000,000.00	30,923,000,000.00	30,587,000,000.00	39,775,000,000.00
Total equity	50.86B	52.34B	51.08B	52.54B	52.96B	52.59B
Retained earnings	44.91B	45.24B	45.92B	46.89B	47.64B	48.23B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	4.02B	3.95B	6.21B	8.36B	8.52B	7.16B	6.69B	6.42B
Depreciation & amortization	1.18B	1.19B	1.78B	2.06B	2.13B	2.17B	2.35B	2.45B
Free cash flow	3.44B	3.32B	5.42B	7.12B	7.40B	5.78B	5.30B	5.26B
Dividends paid	-433.00M	-751.00M	-615.00M	-742.00M	-818.00M	-1.25B	-768.00M	-878.00M
Stock buybacks / issuance	96.00M	2.22B	1.88B	86.00M	31.00M	68.00M	-5.82B	-3.00B
Ending cash balance	788.00M	19.91B	6.04B	2.59B	6.00B	5.86B	2.08B	4.62B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	1.30B	1.34B	1.66B	2.12B	1.32B	1.53B
Depreciation & amortization	591.00M	611.00M	622.00M	623.00M	627.00M	659.00M
Free cash flow	1.05B	1.09B	1.37B	1.75B	1.09B	1.27B
Dividends paid	-194.00M	-229.00M	-229.00M	-226.00M	-226.00M	-283.00M
Stock buybacks / issuance	-1.08B	0	-2.01B	85.00M	0	-894.00M
Ending cash balance	1.99B	2.96B	1.53B	4.62B	5.70B	4.35B

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	9.72	10.58	10.77	15.99	15.73	9.31	7.57	7.08
ROA %	5.61	5.47	5.08	7.87	8.48	5.62	4.81	4.49
ROIC %	7.40	6.70	6.69	10.43	10.80	6.65	5.77	5.49
5-year avg ROE %	11.27	11.07	10.37	11.38	12.51	12.43	11.87	11.14
EBIT margin %	17.34	19.06	21.41	26.61	27.02	22.31	20.62	18.31
FCF / sales %	16.92	18.51	24.31	23.98	23.41	24.20	22.18	21.41
Current ratio	1.47	5.19	1.86	1.43	1.89	1.68	1.40	1.87
Quick ratio	0.79	4.68	1.36	0.89	1.20	1.18	0.83	1.25
Debt / assets	20.36	36.28	29.12	27.98	24.44	23.12	22.11	23.60
LT debt / equity	34.34	77.28	60.22	55.03	41.02	33.02	33.24	37.11
Interest coverage	21.92	31.44	17.35	32.92	40.30	18.64	17.71	16.97
Revenue CAGR (3Y) %	5.71	1.99	12.82	13.31	14.15	2.35	-1.26	-2.67
Net income CAGR (3Y) %	-7.57	5.61	13.52	34.38	33.82	9.32	-15.37	-20.56
FCF CAGR (3Y) %	1.49	4.19	23.06	27.45	30.68	2.19	-9.39	-10.76

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	7.22	6.68	6.84	7.08	7.11	7.63
ROA %	4.63	4.26	4.36	4.49	4.54	4.60
ROIC %	5.69	5.31	5.42	5.49	5.57	5.59
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	20.11	18.19	18.32	18.31	18.54	20.13
FCF / sales %	20.58	20.25	20.67	21.41	21.35	21.77
Current ratio	1.43	1.62	1.52	1.87	1.87	1.65
Quick ratio	0.83	0.96	0.84	1.25	1.28	1.03
Debt / assets	20.83	21.26	21.10	23.60	22.12	28.75
LT debt / equity	31.42	32.20	32.96	37.11	33.17	47.83
Interest coverage	16.80	15.01	16.41	16.97	17.95	17.31
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Diversified

Diagnostics is the largest reported line at 39.36% of revenue, across 3 reported segments.
No single line clears half of revenue; Biotechnology is next at 30.65%, spreading the business across more than one real driver.

Revenue breakdown most recent period

Business

Diagnostics39.36%

Biotechnology30.65%

Life sciences29.99%

Quote time 2026-10-08 10:10:09 · For reference only, not investment advice and not tailored to your situation.